Verrica Pharmaceuticals Inc. Operating Cash Flow
Verrica Pharmaceuticals Inc. (VRCA) reported Operating Cash Flow of -$18.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.28M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.16M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.59M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $9.69M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$17.63M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$60.93M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$38.58M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$18.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$18.44M 10-Q · filed 2026-08-06 | -$23.03M derived: sum of 3 quarters · filed 2026-08-06 | -$13.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$9.16M 10-Q · filed 2026-05-12 | -$13.75M derived: sum of 2 quarters · filed 2026-05-12 | -$4.07M derived: sum of 3 quarters · filed 2026-05-12 | -$14.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $5.09M derived: sum of 2 quarters · filed 2026-03-11 | -$4.95M derived: sum of 3 quarters · filed 2026-08-06 | -$17.63M 10-K · filed 2026-03-11 |
| 2025-09-30 | $9.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$359.00K derived: sum of 2 quarters · filed 2026-08-06 | -$13.04M 10-Q · filed 2025-11-14 | -$29.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$22.72M 10-Q · filed 2026-08-06 | -$38.78M derived: sum of 3 quarters · filed 2026-08-06 | -$47.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$12.68M 10-Q · filed 2026-05-12 | -$28.74M derived: sum of 2 quarters · filed 2026-05-12 | -$37.30M derived: sum of 3 quarters · filed 2026-05-12 | -$53.66M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$16.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$24.62M derived: sum of 2 quarters · filed 2026-03-11 | -$40.98M derived: sum of 3 quarters · filed 2026-03-11 | -$60.93M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$8.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$24.92M derived: sum of 2 quarters · filed 2025-11-14 | -$44.86M 10-Q · filed 2025-11-14 | -$59.37M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$16.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$36.30M 10-Q · filed 2025-08-12 | -$50.81M derived: sum of 3 quarters · filed 2025-08-12 | -$65.62M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$19.95M 10-Q · filed 2025-05-13 | -$34.45M derived: sum of 2 quarters · filed 2025-05-13 | -$49.27M derived: sum of 3 quarters · filed 2025-05-13 | -$53.93M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$29.32M derived: sum of 2 quarters · filed 2025-03-11 | -$33.99M derived: sum of 3 quarters · filed 2025-03-11 | -$38.58M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$14.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$19.48M derived: sum of 2 quarters · filed 2024-11-05 | -$24.07M 10-Q · filed 2024-11-05 | -$29.02M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$4.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$9.26M 10-Q · filed 2024-08-14 | -$14.21M derived: sum of 3 quarters · filed 2024-08-14 | -$12.39M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$4.59M 10-Q · filed 2024-05-13 | -$9.54M derived: sum of 2 quarters · filed 2024-05-13 | -$7.72M derived: sum of 3 quarters · filed 2024-05-13 | -$14.90M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$3.13M derived: sum of 2 quarters · filed 2024-02-29 | -$10.31M derived: sum of 3 quarters · filed 2024-02-29 | -$18.65M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.36M derived: sum of 2 quarters · filed 2023-11-09 | -$13.70M 10-Q · filed 2023-11-09 | -$22.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$15.52M 10-Q · filed 2023-08-08 | -$24.22M derived: sum of 3 quarters · filed 2023-08-08 | -$34.82M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$8.34M 10-Q · filed 2023-05-09 | -$17.04M derived: sum of 2 quarters · filed 2023-05-09 | -$27.64M derived: sum of 3 quarters · filed 2023-05-09 | -$25.14M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$19.30M derived: sum of 2 quarters · filed 2023-03-06 | -$16.80M derived: sum of 3 quarters · filed 2023-03-06 | -$27.58M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$10.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$8.10M derived: sum of 2 quarters · filed 2022-11-07 | -$18.88M 10-Q · filed 2022-11-07 | -$24.98M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$8.29M 10-Q · filed 2022-08-11 | -$14.38M derived: sum of 3 quarters · filed 2022-08-11 | -$21.99M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$10.79M 10-Q · filed 2022-05-09 | -$16.88M derived: sum of 2 quarters · filed 2022-05-09 | -$24.49M derived: sum of 3 quarters · filed 2022-05-09 | -$33.09M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$13.71M derived: sum of 2 quarters · filed 2022-03-02 | -$22.30M derived: sum of 3 quarters · filed 2022-03-02 | -$30.21M 10-K · filed 2022-03-02 |
| 2020-09-30 | -$7.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$16.20M derived: sum of 2 quarters · filed 2021-11-12 | -$24.11M 10-Q · filed 2021-11-12 | -$32.32M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$8.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$16.50M 10-Q · filed 2021-08-10 | -$24.71M derived: sum of 3 quarters · filed 2021-08-10 | -$31.94M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$7.91M 10-Q · filed 2021-05-07 | -$16.12M derived: sum of 2 quarters · filed 2021-05-07 | -$23.35M derived: sum of 3 quarters · filed 2021-05-07 | -$28.40M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$15.44M derived: sum of 2 quarters · filed 2021-03-17 | -$20.49M derived: sum of 3 quarters · filed 2021-03-17 | -$27.41M 10-K · filed 2021-03-17 |
| 2019-09-30 | -$7.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$12.28M derived: sum of 2 quarters · filed 2020-11-09 | -$19.20M 10-Q · filed 2020-11-09 | -$26.10M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$11.97M 10-Q · filed 2020-08-05 | -$18.87M derived: sum of 3 quarters · filed 2020-08-05 | -$24.01M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | -$6.92M 10-Q · filed 2020-05-07 | -$13.82M derived: sum of 2 quarters · filed 2020-05-07 | -$18.96M derived: sum of 3 quarters · filed 2020-05-07 | -$22.64M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$12.04M derived: sum of 2 quarters · filed 2020-03-13 | -$15.72M derived: sum of 3 quarters · filed 2020-03-13 | -$17.87M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$5.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$8.82M derived: sum of 2 quarters · filed 2019-11-06 | -$10.97M 10-Q · filed 2019-11-06 | -$12.82M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | -$3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$5.83M 10-Q · filed 2019-08-07 | -$7.68M derived: sum of 3 quarters · filed 2019-08-07 | -$8.76M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$2.15M 10-Q · filed 2019-05-07 | -$4.00M derived: sum of 2 quarters · filed 2019-05-07 | -$5.08M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$2.92M derived: sum of 2 quarters · filed 2019-03-07 | -$4.58M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$2.74M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$1.66M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |